Common Estrogen Receptor Polymorphism Augments Effects of Hormone Replacement Therapy on E-Selectin but Not C-Reactive Protein

David M. Herrington, MD, MHS; Timothy D. Howard, PhD; K. Bridget Brosnihan, PhD; Donald P. McDonnell, MD; Xiaolin Li, PhD; Gregory A. Hawkins, PhD; David M. Reboussin, PhD; Jianfeng Xu, PhD; Siqun L. Zheng, MD; Deborah A. Meyers, PhD; Eugene R. Bleecker, MD

Background—The estrogen receptor-α (ER-α) IVS1-401 polymorphism identifies a group of women (≈20%) who have augmented effects of hormone replacement therapy (HRT) on levels of HDL cholesterol. This study sought to determine if this augmentation extends to HRT regulation of E-selectin and C-reactive protein (CRP) and to explore possible mechanisms by which this polymorphism might influence estrogen action.

Methods and Results—Serum levels of soluble E-selectin and CRP were measured at baseline and 1 year in 264 postmenopausal women randomized to treatment with oral conjugated equine estrogen (0.625 mg/d), estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/d), or placebo. Women with the ER-α IVS1-401 C/C genotype receiving HRT had nearly a 2-fold greater reduction in E-selectin compared with C/T or T/T women (P for interaction=0.02). In contrast, there was no augmentation of the HRT-associated increase in CRP among the C/C women compared with C/T or T/T women (P for interaction=0.54). Of luciferase reporter constructs containing sequences spanning the IVS1-401 T/C polymorphism, expression of the construct containing the C allele was enhanced 10-fold, with cotransfection of a constitutively expressed B-myb vector. In contrast, B-myb resulted in only a 2.5-fold increase in expression of the T allele construct.

Conclusions—Women with the ER-α IVS1-401 C/C genotype have greater reductions in E-selectin but no further increases in CRP with HRT. The C allele produces a functional binding site for the transcription factor B-myb. The impact of this polymorphism on ER-α transcription and other estrogen-sensitive intermediate and clinical end points has not yet been established. (Circulation. 2002;105:1879-1882.)
Levels of E-Selectin and C-Reactive Protein by Treatment Arm and Estrogen Receptor-α IVS1-401 Genotype

<table>
<thead>
<tr>
<th>IVS1-401C/C (n=47)</th>
<th>IVS1-401C/T or T/T (n=217)</th>
<th>P for Interaction*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E-Selectin, ng/dL†</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRT</td>
<td>47.4 (32.4)</td>
<td>52.8 (31.1)</td>
</tr>
<tr>
<td>Placebo</td>
<td>53.9 (23.7)</td>
<td>51.1 (28.4)</td>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRT</td>
<td>0.35 (0.42)</td>
<td>0.42 (0.53)</td>
</tr>
<tr>
<td>Placebo</td>
<td>0.38 (0.53)</td>
<td>0.40 (1.09)</td>
</tr>
</tbody>
</table>

Values are expressed as median (interquartile range).

*Based on the F-test for the HRT–IVS1-401 genotype interaction term using log E-selectin or log CRP values.

†For E-selectin assays, there were 6 women with missing data (C/C, n=1; C/T or T/T, n=5).

The assay sensitivity is 0.1 ng/mL. The intra-assay coefficient of variation (CV) was 5.5% (mean, 113.3 ng/mL), and the interassay CV was 17.6% (mean, 53.8 ng/mL).

CRP was measured using ELISA and a high-sensitivity kit (American Laboratory Products Co). The assay sensitivity was 0.002 mg/dL. The intra-assay CV was 6.7% (mean, 1.37 mg/dL), and the interassay CV was 12% (mean, 2.23 mg/dL).

DNA was isolated from storeduffy coats with the use of a standard guanidine thiocyanate procedure, and genotyping for the ER-α IVS1-401 T/C polymorphism was performed with polymerase chain reaction followed by digestion with the PvuII restriction enzyme and subsequent sizing of the resulting fragments on an agarose gel.

Statistics

Generalized linear models were used to describe the relationship among on-trial levels of E-selectin and CRP (after adjusting for baseline level), treatment assignment, and ER-α IVS1-401 genotypes. Levels of adhesion molecules and CRP were tested in the log scale; however, means and interquartile ranges in the Table are reported in the original scale. A nominal F-test for the treatment arm scale; however, means and interquartile ranges in the Table are reported in the original scale. A nominal F-test for the treatment arm was used to test for evidence of a drug–gene interaction between HRT and the ER-α IVS1-401 polymorphism. Additional models adjusting for other potentially important confounders including age, race, diabetes, hypertension, body mass index, smoking, physical activity, alcohol consumption, and statin use produced similar results (data not shown). Exploratory data analysis indicated that the effect of unopposed estrogen and estrogen plus MPA were not significantly different; therefore, the 2 active treatment arms were combined. Similarly, preliminary models suggested that the data were best described using a recessive model in which the women with 2 copies of the C allele were contrasted with women carrying 1 or 2 copies of the T allele.

**In Vitro Assays**

To assess the possible impact of the ER-α IVS1-401 T/C polymorphism on myb-activated gene transcription, cultures of CV1 and 293T cells were cotransfected with a B-myb expression plasmid (pcDNA3-B-myb, provided by Dr Roger Watson, Imperial College School of Medicine, London) and 1 of 4 different luciferase reporter constructs derived from the plasmid 5xGal4Luc. In these reporter plasmids, the 5xGal4 response elements were replaced with a simple TATA box, TATA-Luc3 (negative control), 3 copies of the mybA binding site from min1 plus a TK promoter, 3A-TK-Luc3 (positive control), or a TATA box plus the 28 base pair sequences that contain the ER-α IVS1-401 T (common) or C (mutant) alleles, P2-TATA-Luc3 or P1-TATA-Luc3. CMV-R-tag was used to normalize luciferase activity for transfection efficiency.

**Results**

Overall, HRT lowered median E-selectin levels by 14.4% (baseline 51.5 ng/dL; follow-up 44.1 ng/mL; P=0.08). In contrast, HRT raised median CRP levels by 31% (baseline 0.40 mg/dL; follow-up 0.53 mg/dL; P=0.03). There were no significant differences between baseline and follow-up levels of E-selectin or CRP in the placebo group.

The ER-α IVS1-401 C/C genotype was present in 47 (18%) of the women studied. When the data were examined according to ER-α IVS1-401 genotype, women with the C/C genotype had significantly greater reduction in E-selectin than did women with C/T or T/T genotypes (24% versus 14%, P for interaction=0.02; Table 1 and Figure 1). However, there was no evidence of significant modification of estrogen effects on CRP based on IVS1-401 genotype (31% versus 30%, P=0.54; Table 1 and Figure 1).

A database search of transcription factor binding sites revealed that the IVS1-401 C allele produces a potential binding site for myb transcription factors (Figure 2A). Co-

**Figure 1.** Baseline and year 1 levels of log E-selectin and log CRP among women treated with unopposed estrogen or estrogen plus MPA, stratified by ER-α IVS1-401 T/C genotype (C/C, n=47; C/T or T/T, n=217). Data from placebo women are not shown. Error bars are standard errors. P value are from the F-test for the HRT–ER-α IVS1-401 genotype interaction term.
transfection of CV1 cells with a luciferase reporter construct containing the ER-α IVS1-401 C allele (P1-TATA-Luc3) and a myb expression vector produced a >10-fold increase in luciferase activity compared with an only 2.5-fold increase observed in cells transfected with the IVS1-401 T allele (P2-TATA-Luc3) reporter (Figure 2B). The response with the P1-TATA-Luc3 construct is comparable to that observed from a plasmid with 3 copies of a canonical myb-response element arrayed in parallel (3A-TK-Luc3). Similar results were obtained using 293T cells (data not shown).

Discussion
The nearly 2-fold greater reduction in E-selectin among ER-α IVS1-401 C/C women described here closely resembles a similar magnitude effect on HRT-associated increases in HDL described previously. However, the lack of a corresponding augmentation of HRT effect on CRP in ER-α IVS1-401 C/C women indicates that this drug–gene interaction may behave in a selective fashion, augmenting some effects of HRT but not others.

The mechanism by which this polymorphism augments HRT-associated reductions in E-selectin levels or HDL is not yet established. However, the C allele produces a myb binding site that, in the presence of B-myb, is capable of augmenting transcription of a downstream reporter construct 10-fold, suggesting that, in some settings, presence of this allele might amplify ER-α transcription or produce ER-α isoforms that have different properties than the full-length gene product. Because B-myb expression is itself responsive to estrogen activation, a signal-amplifying system producing augmented responses to estrogen in cell types that commonly express B-myb or related transcription factors is possible.

Despite these observations, it remains to be proved that the presence or absence of the IVS1-401 polymorphism alters the quantity or quality of ER-α transcripts or resulting protein. This likely will require experiments with a common cell type from human subjects who vary by the ER-α IVS1-401 genotype. If this can be established, extensive investigation will be warranted to determine which estrogen-sensitive tissues and pathways are affected, including additional studies of inflammation and lipid metabolism, as well as studies in other domains of relevance for estrogen action, including bone metabolism and carcinogenesis. In the meantime, the pattern of intermediate end points described here and previously, including augmented effects on HDL levels and E-selectin expression without a similar augmentation in levels of CRP, suggests a subset of women who may be more favorably affected by hormone therapy with respect to cardiovascular risk. Additional studies in larger cohorts of women are required to determine if these effects on intermediate end points translate into a real reduction in CHD events and whether such a benefit is enhanced or offset by augmented effects in other estrogen-sensitive domains, including risk for fractures, venous thromboembolic events, and breast cancer.

Acknowledgments
Supported in part by R01HL65367 (Principal Investigator: Herrington), National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Md. Dr Herrington has received research support and occasional honoraria from companies that manufacture hormone replacement regimens, including Eli Lilly & Co, Pfizer, Inc, and Wyeth-Ayerst Research. Dr McDonnell has received research support and occasional honoraria from Wyeth-Ayerst Research. We thank Bridget Fitzgerald for performing the DNA isolation and genotyping and Karen Potvin Klein, MA, ELS, for her editorial contributions.

References


Common Estrogen Receptor Polymorphism Augments Effects of Hormone Replacement Therapy on E-Selectin but Not C-Reactive Protein


_Circulation_. 2002;105:1879-1882; originally published online April 8, 2002; doi: 10.1161/01.CIR.0000016173.98826.88

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/105/16/1879

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/